Psychometric Development of Chemotherapy Side Effects Fear Scale - - - Izrada i ispitivanje pouzdanosti i validnosti upitnika za procenu nivoa straha bolesnika od neželjenih dejstava hemoterapije
Journal Title: Acta Facultatis Medicae Naissensis - Year 2017, Vol 34, Issue 1
Abstract
Anxiety, depression and fear in general are the most common emotional problems in people with cancer and it is necessary to recognize them. The patients’ attitude towards the side effects of chemo-therapy has changed significantly in recent years and psychological effects, rather than physiological ones, are becoming increasingly important. The aim of this study was to develop and validate a reliable questionnaire that can measure cancer patients’ fear of the chemotherapy side effects (CheSeFS). A cross-sectional observational study involved 208 oncology and haematology patients at the Clinical Centre of Kragujevac, Serbia and the Institute for Oncology and Radiology of Vojvodina in Sremska Kamenica. The internal reliability of the questionnaire was estimated by calculating Cronbach's alpha coefficient, while the external reliability was calculated by the split-half method with approximately the same number of respondents. In order to test the construct validity of the CheSeFS, all participants filled out the Scale of Depression, Anxiety and Stress-21 (DASS-21) and the Short Subjective Well-being Scale (SSWS), validated in Serbian language. Cronbach’s 𝛼𝛼 coefficient reveals strong internal consistency, with a value of 0.922. The ques-tionnaire demonstrated good structure and uniformity when randomly split into two parts. Exploratory component analysis revealed two factors with the same number of items that explain 61.691% of variance. The components are objective physiological effects of the treatment, and factor that depends on the patient’s psychological and sociological status, with approximately the same percentage of variance. The CheSeFS was positively correlated with the DASS-21 scale (ρ = 0.595, p = 0.000). CheSeFS is a unique, reliable and valid two-factor 14-item instrument, a clinically useful tool to assess fear of the chemotherapy side effects in cancer patients. - - - Anksioznost, depresija i strah su najčešći emocionalni problemi kod bolesnika obolelih od karcinoma i bitno ih je na vreme prepoznati. Stavovi bolesnika o neželjenim dejstvima hemoterapije se značajno menjaju poslednjih godina i sve bitniji su psihološki u odnosu na fiziološke efekte same terapije. Cilj ovog rada bio je da razvije i testira validiran i pouzdan upitnik koji bi sveobuhvatno merio strah bolesnika sa karcinomom od neželjenih dejstava hemoterapije. Sprovedena je opservaciona studija preseka bazirana na izradi, proveri pouzdanosti i validaciji Upitnika za procenu nivoa straha bolesnika od neželjenih dejstava hemoterapije (USNDH) kod ukupno 208 onkoloških i hematoloških bolesnika u Kliničkom centru Kragujevac i Institutu za onkologiju i radiologiju Vojvodine u Sremskoj Kamenici. Unutrašnja pouzdanost upitnika je procenjena izračunavanjem Kron-bahovog koeficijenta (Cronbach ’salpha) za upitnik u celini, dok je eksterna pouzdanost izračunata Split– Halfmetodom sa približno istim brojem ispitanika. U cilju konvergentne validacije korišćena je Skala depresivnosti, anksioznosti i stresa-21 (DASS-21), dok je za diskriminantnu validaciju korišćena Kratka skala subjektivnog blagostanja (KSB) na srpskom jeziku. Kronbahov koeficijent nakon eliminacije određenog broja pitanja iznosio je 0,922. Upitnik je pokazao dobru konstrukciju i homogenost pitanja prilikom nasumičnog deljenja upitnika na dva dela. Eksplorativna faktorska analiza je ukazala na postojanje dva faktora sa jednakim brojem pitanja koja objašnjavaju 61,691% varijansi i to strah od fizioloških efekata same terapije i strah u zavisnosti od psihološko-sociološko-emocionalnog statusa bolesnika, sa približno jednakim procentom varijanse. Na osnovu pozitivnog koefi-cijenta korelacije krajnje verzije upitnika i skale DASS-21 (ρ = 0,595, p = 0,000), dokazana je konvergentna va-lidnost konstrukcije. USNDH je jednostavan, pouzdan i validan dvofaktorski instrument od 14 pitanja čijom kliničkom upotrebom je moguće identifikovati bolesnike sa povišenim nivoom straha, neposredno pre primene novog ciklusa hemoterapije.
Authors and Affiliations
Ivana Vasić, Slobodan Janković, Marija Jelić
Keywords
Related Articles
- EP ID EP347583
- DOI 10.1515/afmnai-2017-0007
- Views 99
- Downloads 0
CANCER OF UNKNOWN PRIMARY SITE SYNDROME- CUP SYNDROME - DIAGNOSTIC AND THERAPEUTICAL DILLEMAS
Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have bee...
Razlozi neadekvatne vakcinacije nakon splenektomije
Cilj ove studije bio je da se analiziraju razlozi zbog kojih se ne prate vodiči za postsplenektomijsku vakcinaciju. Imajuću u vidu da vakcinacija smanjuje rizik od ozbiljnih postsplenektomijskih sepsi, važno je da se o...
ANALYSIS OF STUDENT'S ERRORS IN ENGLISH FOR MEDICAL PURPOSES
Medical students need to be aware not only of their present and future needs during the course of medical English but also of difficulties and problems they possess concerning the knowledge of general English. The aim of...
QUALITY OF LIFE IN TYPE 2 DIABETIC PATIENTS
The presence of diabetes mellitus leads to a decrease in life quality in all domains. The aim of our study was to evaluate the quality of life (QOL) in diabetic patients and the factors affecting it in type 2 diabetic me...
NEW FRONTIERS OF TARGET THERAPY IN ONCOLOGY: ACUTE PROMYELOCYTIC LEUKEMIA
By introduction of all-trans retinoic acid (ATRA) in de novo acute promyelocytic leukemia (APL) an revolution in therapy of this disease has been made. The rate of molecular complete remissions (CR) have been doubled com...